ATE224203T1 - Bei raumtemperatur lagerfähiges immunoglobolin- präparat für intravenöse injektion - Google Patents

Bei raumtemperatur lagerfähiges immunoglobolin- präparat für intravenöse injektion

Info

Publication number
ATE224203T1
ATE224203T1 AT98119782T AT98119782T ATE224203T1 AT E224203 T1 ATE224203 T1 AT E224203T1 AT 98119782 T AT98119782 T AT 98119782T AT 98119782 T AT98119782 T AT 98119782T AT E224203 T1 ATE224203 T1 AT E224203T1
Authority
AT
Austria
Prior art keywords
intravenous injection
preparation
immunoglobolin
room temperature
temperature storable
Prior art date
Application number
AT98119782T
Other languages
English (en)
Inventor
Yutaka Hirao
Motonori Hashimoto
Tae Kitamura
Yahiro Uemura
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=17768099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE224203(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Application granted granted Critical
Publication of ATE224203T1 publication Critical patent/ATE224203T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Water Supply & Treatment (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98119782T 1997-10-23 1998-10-23 Bei raumtemperatur lagerfähiges immunoglobolin- präparat für intravenöse injektion ATE224203T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP29137497 1997-10-23

Publications (1)

Publication Number Publication Date
ATE224203T1 true ATE224203T1 (de) 2002-10-15

Family

ID=17768099

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98119782T ATE224203T1 (de) 1997-10-23 1998-10-23 Bei raumtemperatur lagerfähiges immunoglobolin- präparat für intravenöse injektion

Country Status (11)

Country Link
US (2) US6159471A (de)
EP (1) EP0911037B2 (de)
KR (1) KR100632312B1 (de)
CN (2) CN1149100C (de)
AT (1) ATE224203T1 (de)
CA (1) CA2251342A1 (de)
DE (1) DE69808012T3 (de)
DK (1) DK0911037T3 (de)
ES (1) ES2182202T5 (de)
HK (1) HK1021698A1 (de)
PT (1) PT911037E (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281336B1 (en) 1998-06-09 2001-08-28 Statens Serum Institut Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
ES2184594B1 (es) * 2001-01-17 2004-01-01 Probitas Pharma Sa Procedimiento para la produccion de gammaglobulina g humana inactivada de virus.
US20040156835A1 (en) * 2001-05-30 2004-08-12 Taiji Imoto Protein preparation
TW200300173A (en) * 2001-11-13 2003-05-16 Nisshin Oillio Ltd Process for producing concentrated/purified protein using clay mineral composition
EP1475101B1 (de) 2002-02-14 2010-10-27 Chugai Seiyaku Kabushiki Kaisha Antikörper enthaltende pharmazeutische lösungen
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
FR2854801B1 (fr) * 2003-05-12 2006-09-01 Khorionyx Implant injectable de globine insoluble
EP1532983A1 (de) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulinpräparationen mit erhöhter Stabilität
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
DE102004022927A1 (de) * 2004-05-10 2005-12-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg 1,4 O-verknüpfte Saccharose-Derivate zur Stabilisierung von Antikörpern oder Antikörper-Derivaten
US7723306B2 (en) 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
WO2008001496A1 (en) * 2006-06-28 2008-01-03 Fujimori Kogyo Co., Ltd. Liquid container
WO2008100578A2 (en) * 2007-02-14 2008-08-21 Amgen Inc. Method of isolating antibodies by precipitation
NZ598881A (en) 2007-03-29 2013-11-29 Abbvie Inc Crystalline anti-human il-12 antibodies
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
AU2011212440B2 (en) 2010-02-04 2015-01-22 Csl Behring Ag Immunoglobulin preparation
EP2361636A1 (de) 2010-02-26 2011-08-31 CSL Behring AG Immunglobulinpräparat und Aufbewahrungssystem für ein Immunglobulinpräparat
US8796430B2 (en) 2010-05-26 2014-08-05 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
NZ609469A (en) 2010-11-11 2015-02-27 Abbvie Biotechnology Ltd Improved high concentration anti-tnfα antibody liquid formulations
ES2641042T3 (es) * 2011-06-24 2017-11-07 Asahi Kasei Kuraray Medical Co., Ltd. Procedimiento para la fabricación de un fármaco proteínico
TWI629283B (zh) 2012-02-23 2018-07-11 巴克斯歐塔公司 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱
CN103341187B (zh) * 2012-06-28 2016-06-22 四川远大蜀阳药业股份有限公司 一种终端灭活病原微生物的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4378346A (en) * 1979-08-15 1983-03-29 Tankersley Donald L Intravenously injectable solution of plasma protein fraction free from bradykinin, kininogen and prekallikrein activators and processes for its production
FR2582515B1 (fr) * 1985-05-30 1988-11-04 Merieux Inst Procede de preparation de gamma-gobulines administrables par voie intraveineuse et gamma-globulines obtenues
JPH0662436B2 (ja) * 1986-05-19 1994-08-17 株式会社ミドリ十字 静注用免疫グロブリン製剤の製造方法
DE3641115A1 (de) * 1986-12-02 1988-06-16 Lentia Gmbh Verfahren zur herstellung eines intravenoes anwendbaren und in fluessiger form stabilen immunglobulins
JP2547556B2 (ja) * 1987-02-06 1996-10-23 株式会社 ミドリ十字 ｒ−グロブリンの液状製剤
JP2613409B2 (ja) * 1987-11-20 1997-05-28 株式会社ミドリ十字 抗エイズウイルス抗体陽性静注用免疫グロブリン製剤の製造方法
US5177194A (en) * 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
DE4125625C2 (de) † 1991-08-02 1999-12-02 Octapharma Ag Glarus Verfahren zur Herstellung von virusinaktivierten Immunglobulinlösungen
JPH0761935A (ja) * 1993-08-25 1995-03-07 Green Cross Corp:The 静注用免疫グロブリン製剤の製造方法
JP4003235B2 (ja) * 1994-09-30 2007-11-07 三菱ウェルファーマ株式会社 静注用免疫グロブリン製剤の製造方法
EP0764658B1 (de) * 1995-09-22 2002-01-02 ZLB Bioplasma AG Verfahren zur Gewinnung von Immunglobulinen aus Fraktionen, die bei der Fraktionierung von menschlichem Blutplasma entstehen
CA2232420A1 (en) * 1997-03-19 1998-09-19 The Green Cross Corporation Immunoglobulin preparation and preparation process thereof

Also Published As

Publication number Publication date
EP0911037B1 (de) 2002-09-18
CN1149100C (zh) 2004-05-12
CN1224620A (zh) 1999-08-04
KR100632312B1 (ko) 2007-05-14
EP0911037A1 (de) 1999-04-28
CA2251342A1 (en) 1999-04-23
US6159471A (en) 2000-12-12
DK0911037T3 (da) 2002-12-02
US6485725B1 (en) 2002-11-26
DE69808012T2 (de) 2003-08-14
ES2182202T3 (es) 2003-03-01
ES2182202T5 (es) 2007-12-01
DE69808012D1 (de) 2002-10-24
PT911037E (pt) 2002-12-31
CN1520885A (zh) 2004-08-18
EP0911037B2 (de) 2007-06-13
HK1021698A1 (en) 2000-06-30
DE69808012T3 (de) 2008-01-24
KR19990037317A (ko) 1999-05-25

Similar Documents

Publication Publication Date Title
ATE224203T1 (de) Bei raumtemperatur lagerfähiges immunoglobolin- präparat für intravenöse injektion
DE69834741D1 (de) Cellulase aus actinomycetes und herstellungsverfahren dafür
DE69829308D1 (de) Cellulase aus actinomycetes und herstellungsverfahren dafür
EP1408108A3 (de) Cellulase aus Actinomycetes und Herstellungverfahren
ATE369423T1 (de) Verfahren zur herstellung von schutzproteine enthaltende immunoglobuline und ihre verwendung
DK0741515T3 (da) Transgen produktion af antistoffer i mælk
DE122004000017I1 (de) Monoklonaler Antik¦rper gegen ein Cytotoxin, denselben erzeugendes Hybridoma und Verfahren f}r die Herstellung des gereinigten Cytotoxin.
EP0850653A3 (de) Katheterübergangssystem
PT733069E (pt) Antigenios ctla-8 de primata purificados e reagentes relacionados
FR2690920B1 (fr) Dérivés 1-hydrocarbyloxy-2,2,6,6-tétraméthylpipéridiniques de 1,3,5-triazines non-migrants comme stabilisants de matières polymères.
ATE154526T1 (de) Aktivierte trägermaterialien, ihre herstellung und verwendung
DK0530447T3 (da) Fremgangsmåde til rensning af IgG-monoklonale antistoffer
DE69419966T2 (de) Impstoff gegen Streptococcus suis-Infektion
DE69632643T2 (de) Verwendungen von nukleinsäuren die ein retrovirus aus schweinen entnommen sind
DE50107689D1 (de) Haemostatisch aktives vwf enthaltendes präparat und verfahren zu seiner herstellung
ATE7184T1 (de) Waermeschrumpfbarer artikel und verfahren zu dessen herstellung.
ATE137221T1 (de) Verfahren zur herstellung von 2-chlor-5-methyl- pyridin
ATE30870T1 (de) Strahlungsvernetzung von polyamiden.
DK38889A (da) Onkogen-indkodet polypeptid med vaekstfaktoraktivitet
DK0676965T3 (da) Fremgangsmåde til at reducere immunogeniciteten af variable regioner på antistoffer
DE59309133D1 (de) Granulozytenbindende Antikörperkonstrukte, ihre Herstellung und Verwendung
NO178231C (no) Umettede polyesterharpiksblandinger og anvendelse av disse
DE69503093D1 (de) Verfahren zur Herstellung von Guaniden
EP0389640A4 (en) Resin composition having excellent heat stability and weatherability
DK0643751T3 (da) Fremgangsmåde til limning af træbaserede produkter

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0911037

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 0911037

Country of ref document: EP